Antibodies directed toward the HIV-1 GP120 CD4 binding site with increased potency and breadth
Embodiments of the present invention are directed to compositions and methods for anti-HIV (anti-CD4 binding site) potent VRC01-like (PVL) antibodies targeted to gp120 having an amino acid substitution in the heavy chain at a residue in the anti-CD4 binding site PVL antibody that is equivalent to Phe43 in CD4 and an amino acid substitution in the light chain, these antibodies having improved potency and breadth.
Application title: Anti-hiv antibodies having increased potency and breadth. US Grant. Application number US13714398. Priority date 2011-07-25. Filing date 2012-12-13. Publication date 2016-11-15. Grant date 2016-11-15. Government Interests: This invention was made with government support under P01 A1081677-01, awarded by the National Institutes of Health. The government has certain rights in the invention. Parent Case Text: The present application claims priority to and the benefit of U.S. Provisional Application Ser. No. 61/570,173 filed on Dec. 13, 2011, and is continuation in part of U.S. patent application Ser. No. 13/558,312, filed Jul. 25, 2012, the entire contents of both of which are incorporated herein by reference.
Published - US9493549.pdf